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The aim of this study was the evaluation of the impact of service screening programmes on breast cancer mortality in five regions of
Italy. We conducted a matched case–control study with four controls for each case. Cases were defined as breast cancer deaths
occurred not later than 31 December 2002. Controls were sampled from the local municipality list and matched by date of birth.
Screening histories were assessed by the local, computerised, screening database and subjects were classified as either invited or
not-yet-invited and as either screened or unscreened. There were a total of 1750 breast cancer deaths within the 50 to 74-year-old
breast cancer cases and a total of 7000 controls. The logistic conditional estimate of the cumulative odds ratios comparing invited
with not-yet-invited women was 0.75 (95% CI: 0.62–0.92). Restricting the analyses to invited women, the odds ratio of screened to
never-respondent women corrected for self-selection bias was 0.55 (95% CI: 0.36–0.85). The introduction of breast cancer
screening programmes in Italy is associated with a reduction in breast cancer mortality attributable to the additional impact of service
screening over and above the background access to mammography.
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Breast cancer screening has been shown in several randomised
clinical trials (RCTs) conducted between the mid-1960s and
mid-1980s to be effective in reducing breast cancer mortality
(IARC, 2002).
Mammographic screening is now widespread in western
countries but access modalities differ. In the United States, the
use of screening is based on spontaneous access to mammographic
facilities, usually associated with a clinical breast examination and
with different guidelines on age range and screening interval
(Smith-Bindman et al, 2003; Smith et al, 2007). In Europe service
screening is a public health initiative, offering two-views
mammography every 2 years, in which all women of the target
population (in Italy, 50–69 years of age) are invited to participate
(Perry et al, 2006). Programme performance indicators have been
developed in accordance with European guidelines and assess-
ments have been reported (Lynge et al, 2003; Giordano et al, 2006).
The first screening programme in Italy was started at the
beginning of the 1990s in the cities of Florence and Turin, and
since then other programmes have been started in other regions. In
2006 the National Centre for Screening Monitoring reported a
coverage of more than 90% of the target population in northern
and central Italy (Zappa and Rosselli Del Turco, 2007).
Now that screening is widespread, two questions become
relevant: (a) are the effects of breast cancer screening under
usual conditions within the community comparable with
those detected by the RCTs (Harris, 2005), and (b) is service
screening able to have an additional impact over and above
the background, spontaneous use of mammography in the
population?
There are several methods to assess the effectiveness of
screening for reducing breast cancer mortality. In particular,
incidence-based mortality and geographical comparisons have
been used (Paci et al, 2002; Duffy et al, 2002a; Olsen et al, 2007).
However, the case–control study is a traditional tool for the
evaluation of screening outcome (Collette et al, 1984; Verbeek
et al, 1984; Palli et al, 1986), although with high methodological
complexity (Walter, 2003; Fielder et al, 2004; Elmore et al, 2005),
and was used in several studies at the end of the eighties. The
case–control study design has been used because of its efficiency.
The collection of screening histories of a limited number of
controls allows a more accurate and valid evaluation than it is
possible for the whole invited or screened population. Several Received 13 May 2008; revised 20 June 2008; accepted 30 June 2008
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sstatistical simulations, like the one by Connor et al, (2000), have
shown that, with adequate study design, the case–control study
results are comparable to the observed in prospective cohort
studies. Estimates of mortality reduction from randomised trials
and case–control studies have been compared in review (Demissie
et al, 1998).
The aim of this case–control study has been to evaluate the
effectiveness of service screening programmes in reducing breast
cancer mortality in the Italian areas participating in the IMPACT
study. The outcome is interpreted as the additional impact of the
organised programme offered to the community over and above
the usual care in that population, that is, the existing, background
access of target women to mammography.
MATERIALS AND METHODS
The IMPACT study
The IMPACT database (Zorzi et al, 2006) was collected from
cancer registries data of in situ and invasive breast cancer cases
diagnosed between 1988 and 2001 in women aged 40–79, resident
in 17 areas mainly located in central and northern Italy. All cases
were followed up for living status and the specific cause of death
was obtained from the regional mortality registers. All cases were
linked to the screening files and classified by detection method as
either screen-detected, not screen-detected but with at least one
screening test, never-respondent to the screening invitation or
diagnosed before the screening invitation.
The case–control study design
All areas where both screening and a cancer registry were active
were included in the case–control study. The study base was the
dynamic population of women aged 50–74 years resident in the
selected areas between the year before the start of service screening
and 2001 (i.e., all women who were resident in the areas for any
period of time during the study period were eligible for the study).
Cases were defined as breast cancer deaths as reported in death
certificates occurred not later than 31 December 2002 in the study
base. To check for the information bias because of possible
misclassification of cause of death, all deaths within breast cancer
cases diagnosed in the study base were included in the study and a
sensitivity analysis using deaths for whatever cause was performed.
Each case was matched to four controls using incidence–density
sampling. The risk set for each case was defined as the women
resident in the municipality in the subject’s year of death. Controls
were individually matched to the fatal breast cancer cases by area
of residence and date of birth (±3 months). All controls had to be
free of breast cancer up to the date of diagnosis of the matched
case (the eligibility was assessed by linkage with the cancer
registry).
Cases and controls were only enrolled if they were resident in
their municipality from at least 2 years before the date of case
diagnosis or from the screening programme start date.
Definition of exposure
The service screening histories of cases and controls, including the
date of their first invitation and the dates of all their screening tests
following the invitation, if any, were extracted from the local,
computerised, screening database. All and only mammography
tests performed in service screening, that is, following an invitation
to be screened, were included in the analysis, regardless of the
actual test result.
The date of incidence reported in the cancer registry and the
date of pseudodiagnosis for controls (i.e., the date of censoring the
screening history for controls) were selected as the index dates for
the classification of subjects as either invited or not-yet-invited
and as either screened or unscreened.
Statistical modelling using microsimulation has been imple-
mented by Connor et al. (2000) showing how estimates of
mortality odds ratios are influenced by the choice of a time
window in which controls are eligible to be screened. If a matched
case is detected clinically, the date of pseudodiagnosis of the
control should be defined as the date of diagnosis of the matched
case (so excluding later screening test). Screen-detected breast
cancer cases live without symptoms in a period corresponding to
the diagnostic anticipation. Therefore detection at screening
shortens a matched control’s opportunity to be screened. On the
basis of the results of microsimulation, Connor et al (2000)
postulated that the definition of exposure to screening should
include any screen up to the time the case would have been
clinically diagnosed in the absence of screening. To compensate
for the lead time owing to screen detection, the pseudodiagnosis
date of the controls matched to each screen-detected case was
postponed for 1 year by allowing the controls to be screened for a
duration comparable with the preclinical detectable phase.
Statistical analyses
We present firstly the analysis by allocation, that is, invited vs not-
yet-invited women. In Italy, a large proportion of women waited
for 2–4 years after the official programme start date before
receiving their invitation to an appointment for the mammography
test. This waiting time was an expected logistical and organisa-
tional consequence of enrolling the whole target population.
Our second analysis is the comparison of the mortality for
breast cancer between screened and unscreened women (i.e.,
never-respondent plus not-yet-invited women). The inclusion of
not-yet-invited women in the reference category with the never-
respondent women would likely decrease the possible distortion of
the comparison, but the combining of the two groups is not, per se,
a guarantee of an unbiased estimate. In fact, respondent women
might be different from never-respondent women because of the
so-called ‘self-selection bias’: those screened have elected to be
screened whereas those never screened (after the invitation) have
refused the offer to be screened, thereby introducing a self-
selection bias into the allocation of exposure (Cuzick et al, 1997).
Finally we compare screened with never-respondent women.
The method proposed by Duffy et al (2002b), to correct for
selection bias and thus obtain the effect of screening in potential
attendees, was applied. The odds ratio corrected for selection
bias was estimated with the following formula, where p is the
attendance rate and j is the crude uncorrected odds ratio and
Dr is the mortality differential between never-respondent and
not-yet-invited women:
RRc ¼
p   j   Dr
1  ð 1   pÞ
  Dr
To estimate the mortality differential Dr, the odds ratio of never-
respondent to not-yet-invited women was calculated.
The odds ratios and 95% confidence intervals were calculated
using conditional logistic regression retaining individual matching
for birth cohort and area of residence. The statistics package used
for the analyses was STATA 9.2.
RESULTS
A total of 2371 deaths within breast cancer cases diagnosed in the
target population of women aged 50–74 years were included in the
study. Four controls were matched to each case by date of birth
and municipality of residence for a total of 9484 controls (1:4).
A total of 1750 (73.8%) deaths were caused by breast cancer.
Effectiveness of service screening
D Puliti et al
424
British Journal of Cancer (2008) 99(3), 423–427 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sPatient characteristics and screening history by case–control
status are presented in Table 1. The year of screening activation is
different between programmes and it varies from the early 1990s in
Tuscany and Piedmont to the late 1990s in Veneto. The average age
at diagnosis/pseudodiagnosis was 62.3 years for cases and 62.2
years for controls. The 37.5 and 39.6% among cases and controls
respectively had been invited to screening. Considering invited
women only, 54.8 and 38.0% had never attended to screening
among cases and controls respectively. Mean age at first screening
was 59.2 for cases and 60.0 for controls.
Screen-detected cases accounted for 10.3% of breast cancer
deaths, 6.6% were diagnosed in not screen-detected women with at
least one screening test and 20.6% in never-respondent women.
The remaining breast cancer deaths occurred among the not-yet-
invited women. Among the case subjects who died for breast
cancer, 173 (9.9%) were classified as early cancer at diagnosis
(stage less than II) and 1301 (74.3%) were stage IIþ. The average
age at death was 65.2 and average time from diagnosis to death was
2.9 years (range: o1–12 years), with mean times of 3.2 years for
screen-detected breast cancer cases, 2.4 years for never-respondent
women and 3.0 years for not-yet-invited women.
The logistic conditional estimate of the odds ratios for risk of
breast cancer deaths comparing invited with not-yet-invited
women was 0.75 (95% CI: 0.62–0.92), a 25% mortality reduction,
and the odds ratio comparing screened with unscreened women
was 0.50 (95% CI: 0.42–0.59) (Table 2). These odds ratios do not
vary significantly by age group (homogeneity test: P¼0.278 and
P¼0.196, respectively).
The odds ratios comparing screened with never-respondent
women were performed including only cases and controls
with at least one invitation to screening (N cases¼657), to ensure
that all subjects were comparable with respect to screening
opportunity. The odds ratio of screened to never-respondent
women was 0.46 (95% CI: 0.38–0.56), a 54% mortality reduction
(Table 2). According to Duffy et al (2002b), the correction for
selection bias brought to an estimate of the corrected odds ratio
for screened to never-respondent women equal to 0.55 (95% CI:
0.36–0.85), a 45% mortality reduction, confirming the protective
effect of screening for those women attending (Table 2). This
corrected estimate has been obtained assuming 65% of attendance
and estimating the mortality differential through the odds ratio
of never-respondent to not-yet-invited women (1.11, 95% CI:
0.87–1.40).
We performed a sensitivity analysis including deaths within
breast cancer cases for whatever cause. The probability of dying for
all causes for invited vs not-yet-invited women was 0.83 (95% CI:
0.70–0.98) and for screened vs unscreened women was 0.63 (95%
CI: 0.55–0.73).
DISCUSSION
Data from this study has been extracted from the Italian IMPACT
database where all breast cancer cases have been classified by
detection method and staged. The definition of the exposure to
screening is based on computerised records of screening service.
Breast cancer cases have been obtained from cancer registries
(independent sources) and linked blind to the screening histories.
With a study size of 1750 cases and 7000 matched controls, the
study has 90% power (a¼0.05) to detect an 18% difference in
mortality between invited and not-yet-invited women.
The results of this study show that service screening is
associated with a 25% reduction in the probability of dying for
breast cancer by allocation to screening invitation and with a 45%
reduction when comparing screened with never-respondent
women after correction for selection bias.
The analysis by allocation allows an estimation of how much the
organised screening programme has added to the background use
of mammography. It should be considered as equivalent to an
intention-to-treat, non-randomised analysis (Selby, 1994). Invited
women included never-respondent women. Only screened cases
benefit from a screening programme, and therefore the estimate of
the impact of service screening is conditioned by the rate of
compliance to the invitation. According to this analysis, our study
has shown a reduction of breast cancer mortality within the range
Table 1 Patient characteristics, screening history by case–control status
Cases Controls
Region, N (%) Screening activation
Emilia-Romagna 1995 784 (44.8) 3136 (44.8)
Piedmont 1992 418 (23.9) 1672 (23.9)
Tuscany 1990 454 (25.9) 1816 (25.9)
Umbria 1997 42 (2.4) 168 (2.4)
Veneto 1999 52 (3.0) 208 (3.0)
Mean (range) age at diagnosis
or pseudodiagnosis
62.3 (50–74) 62.2 (49–75)
Invitation status, N (%)
Not-yet-invited 1093 (62.5) 4228 (60.4)
Invited 657 (37.5) 2772 (39.6)
Number of screening visits among invited, N (%)
0 360 (54.8) 1054 (38.0)
1 212 (32.3) 1123 (40.5)
2 52 (7.9) 397 (14.3)
3+ 33 (5.0) 198 (7.1)
Mean (range) age at first
screening
59.2 (50–71) 60.0 (49–71)
Mode of detection, N (%)
Screen-detected 181 (10.3)
Not screen-detected with
at least 1 screening test
116 (6.6)
Never respondent 360 (20.6)
Not-yet-invited 1093 (62.5)
TNM stage, N (%)
Early (stage 0–I) 173 (9.9)
Advanced (stage II+) 1301 (74.3)
Unknown 276 (15.8)
Mean (range) age at death 65.2 (50–85)
Table 2 The odds ratios for risk of breast cancer death by screening
history
No of cases/
controls
Odds ratio
(95% CI)
Analysis by allocation
Not-yet-invited 1093/4228 1
Invited
a 657/2772 0.75 (0.62–0.92)
Analysis by screening status
Unscreened
b 1453/5282 1
Screened 297/1718 0.50 (0.42–0.60)
Analysis by screening status among invited women only
Never respondent 360/761 1
Screened 297/1307 0.46 (0.38–0.56)
Screened (self-selection corrected) 0.55 (0.36–0.85)
aScreened+never-respondent.
bNever-respondent+not-yet-invited.
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2002). The summary estimate of the breast cancer mortality
reduction, after pooling the results from eight RCTs, is equal to
24% (31–17%) (Demissie et al, 1998).
The analyses by exposure to screening measures the benefit of
screening among women who agree to be screened, and therefore
the result may be affected by self-selection bias. We followed two
different strategies to deal with this possible bias: the comparison
of the mortality for breast cancer between screened and
unscreened women, that is, never-respondent plus not-yet-invited,
and the comparison of screened women with those never-
respondent among the invited women corrected for self-selection
(Duffy et al, 2002b). Both the estimates showed that service
screening is effective in reducing breast cancer mortality by about
45–50% in women attending after invitation.
In other recent case–control screening studies, there has been
a range of results from small (Elmore et al, 2005) to large
benefit (Fielder et al, 2004; Allgood et al, 2008). Elmore’s study
assesses the efficacy of screening in a context where the screening
is based on spontaneous access to mammographic facilities, and
the subject’s screening history has been extracted from medical
records. The lack of a reduction in breast cancer mortality may be
partly because of a differential misclassification of the status of
screening exposure. In contrast, in the case–control studies where
the aim is to evaluate service-screening programmes, only
mammography tests performed following an invitation have been
included in the analysis. The design of these studies is rather
similar to ours; in UK the study by Allgood et al (2008) estimated a
65% reduction of breast cancer mortality in women attending
screening, whereas the study by Fielder et al (2004) estimated
a 38% reduction.
Screened and never-respondent women could have a different
background access to mammography, as well as other differences
related to the measure of the screening effect. To fully control this
selection bias, we performed the analysis using the method
proposed by Duffy et al (2002b). This method of correction for
self-selection bias, which has been used in several case–control
studies (Fielder et al, 2004; Allgood et al, 2008), makes the crucial
assumption that the relative excess mortality for ‘non-compliers’
compared with a population not invited for screening is the same
in the programme in question as in the RCTs (pooled estimate:
36%). The estimate of the relative mortality obtained from
RCTs is too high for the Italian service-screening programme
where the participation rate is lower and therefore the difference
between compliers and non-compliers is not expected to be
so large. From the information available in our dataset, we
estimated a 11% relative excess mortality for never-respondent
women and we used this internal estimate in the correction for
self-selection bias.
Exposure is theoretically defined as screening (invitation or
test) that takes place within that period before the time at
which the case would have been diagnosed in the absence of
screening. In empirical studies the time of diagnosis in the absence
of screening for cancer is not observable and it is necessary,
therefore, to use estimates of the average duration of the
preclinical phase. We have assumed a 1-year time lag in exposure
for controls matched to screen-detected cases. To evaluate the
impact on the odds ratio of different time lags, we performed a
sensitive analysis. The estimates of the odds ratios comparing
invited with not-yet-invited women were 0.82 and 0.72 using time
lags of 6 months and 1.5 years, respectively. The odds ratios
comparing screened to unscreened women were 0.54–0.49,
respectively.
We considered the possible information bias due to misclassi-
fication of cause of death (Gill and Horwitz, 1995). Extending the
analysis to deaths for whatever cause, we obtained an estimate of
17% for the mortality reduction for invited women and 37% for
screened women. A possible bias in the attribution of the cause of
death cannot be excluded, but it seems implausible that it could
explain all of the observed benefit.
We also considered the possibility that improvements in breast
cancer treatment could have affected our estimate on the impact of
screening, as far as the comparison of invited vs not-yet-invited is
concerned. As a matter of fact the median year of diagnosis is 1
year more recent for invited with respect to not-yet-invited
women. We do not think that important treatment improvements
had occurred in so short a period. Furthermore, we previously
showed in two of the areas participating in the IMPACT study that
the improvement in survival rates were almost completely
explained by stage distribution and not by increase of the survival
rate by stage (Paci et al, 2005).
Few screen-detected breast cancer cases were dead at the
end of follow-up (10.4% of the total deaths), and the majority
of deaths were among the not-yet-invited and never-respondent
women. This is the expected outcome if early diagnosis
by mammographic screening is changing the probability of
dying for breast cancer. Longer follow-up can confirm that
service screening will continue to achieve a reduction of mortality
for breast cancer.
In conclusion, the present study shows that the introduction
of breast cancer screening programmes in Italy is associated
with a reduction in breast cancer mortality, consistent with the
results of randomised trials of mammographic screening and
attributable to the additional impact of service screening over and
above the background access to mammography.
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